As a key biomarker in urinary system diseases, TMAO suppresses Megalin expression via PI3K and ERK signaling, activates the MAPK-NLRP3 pathway to induce renal oxidative stress and inflammation, and ultimately leads to renal fibrosis. Here, LRP2 is linked to urinary system disorder.